Barclays maintains Iovance Biotherapeutics at Overweight, raises price target to $19 from $18

Barclays raised its price target for Iovance Biotherapeutics to $19 from $18, maintaining an Overweight rating. This implies a 145.5% upside from the Nov 5 close of $7.74. Recent analyst price targets for the company range from $8 to $18.

Original reporting
Published Nov 6, 2026, 4:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 4:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Iovance Biotherapeutics at Overweight, raises price target to $19 from $18 — source image
Decision brief

The 30-second read

Low
01

Why it matters

Analyst target increase suggests potential upside but lacks new operational catalysts.

02

Market read

Minor catalyst for IOV; limited broader market impact.

03

What to watch

No new clinical data; price move may be speculative.

Relevance 5/10Novelty 5/10Timing: today

Background

Iovance Biotherapeutics is a small‑cap biotech focused on cell therapies.

Market effects

May lift sentiment in the biotech sector.

Limited to US biotech investors.

Low

Counterpoint

Target raise could be premature if upcoming trial data disappoint.

Key entities

  • Barclays

    Raised price target to $19.

Related articles

$SLSHighAI 8/10

SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too

BlackRock and a Vanguard unit added SLS, IBRX, IOVA, MRK, and LLY to their Q3 buy lists. Lilly reported strong sales from diabetes, obesity, and cancer drugs. Sellas (SLS) awaits Phase 3 trial results for its AML treatment. ImmunityBio (IBRX) plans expanded FDA approval for Anktiva. Iovance (IOVA) saw 77% YoY sales growth for Amtagvi and is testing it with Merck's (MRK) Keytruda. Retail sentiment varies across stocks.

$IOVAHighAI 8/10

IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs

Iovance Biotherapeutics (IOVA) reported Q3 2026 earnings with a loss of 5 cents per share, narrower than estimates. Revenue rose 80.1% YoY to $121.5M, driven by Amtagvi sales. R&D costs fell 34.4% YoY. IOVA reaffirmed 2026 revenue guidance of $410M-$420M. Shares fell 11% despite strong results.

$IOVAMedAI 8/10

Iovance Biotherapeutics Inc (IOVA) (Q3 2026) Earnings Call Highlights: Record $122

Iovance Biotherapeutics (IOVA) reported Q3 2026 revenue of $122M, up 80% YoY, with Amtagvi US revenue crossing $100M. Interim CEO Vogt confirmed no impact from past maintenance issues and expects sequential growth. CFO Roche noted improved profitability. Proleukin sales rose to $20M, aligning with Amtagvi demand. LUN-202 data expected next year, with BLA submission planned for 2027. Community hospital infusions are growing, currently at 1/3 of total. Cash runway extended into 2029.

$IOVAMed

Iovance Biotherapeutics (IOVA) Lifileucel Wins Fast Track After Strong Sarcoma Trial Data

Iovance Biotherapeutics (IOVA) announced that its treatment lifileucel showed strong efficacy in advanced soft tissue sarcomas, according to a pilot study. The FDA granted lifileucel fast track designation for these sarcomas. IOVA reported Q3 2026 revenue of $121.47M and a net loss of $22.27M. The company is expanding its TIL platform beyond melanoma into other solid tumor indications.

$IOVAHighAI 8/10

IOVANCE BIOTHERAPEUTICS, INC. (IOVA): Corporate Overview November 2026 Exhibit 99.1

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an SEC Form 8-K — Other Events. Corporate Overview November 2026 Exhibit 99.1 Exhibit 99.1 Forward-Looking Statements Certain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meani

$IOVAHighAI 8/10

Iovance (IOVA) Q3 2026 Earnings Call Transcript

Iovance (IOVA) reported Q3 2026 revenue of $122M, up 80% YoY, with AMTAGVI sales at $102M. The company expects to expand its ATC network to 110+ centers by year-end. Clinical trials for lifileucel in non-small cell lung cancer and sarcoma showed promising results, with FDA fast-track designations granted. Iovance plans sBLA submissions in 2027 and 2028-2029. The company's cash runway is expected to extend into 2029.